ArticleGenome biology2026
A cytoplasmic index for quantifying immune-related A-to-I RNA editing.
Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A cytoplasmic index for quantifying immune-related A-to-I RNA editing.Genome biology · 2026Article
- RNA Therapeutics Targeting Skeletal Muscle: Emerging Antisense and Gene-Modifying Strategies.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDistinguishing self from non-self is a major challenge for the immune system. Endogenous cytoplasmic double-stranded RNA (dsRNA) can mimic viral RNA and activate immune sensors like MDA5. ADAR1-mediated adenosine-to-inosine editing disrupts base-pairing to suppress immunogenicity of these endogenous structures. Global editing indices are widely used to probe this crucial ADAR1 function. However, they are dominated by nuclear pre‑mRNA edits with limited immune relevance. Here we present the cytoplasmic editing index (CEI) that quantifies editing specifically within inverted Alu repeats in 3' untranslated regions of mature cytoplasmic transcripts, which potentially form cytosolic dsRNA structures carrying higher immunological risk.
resultsAnalyzing over 25,000 RNA-sequencing samples, we demonstrate CEI captures ADAR1p150 activity and outperforms the global editing index in terms of sensitivity and signal-to-noise, enabling sharper tissue-specific profiling, enhanced detection power of infection‑induced editing changes, and stronger association with cancer prognoses. An open-source, cloud-native pipeline delivers end‑to‑end, reproducible analysis at very low cost, supporting immediate, scalable adoption.
conclusionsCEI provides a refined metric for quantifying immune-relevant RNA editing, revealing previously obscured tissue- and disease-specific editing landscapes. The accompanying open-source, cloud-native pipeline enables broad adoption of high-quality editing analysis across research settings. This approach offers new opportunities for investigating ADAR1's role in immunity, infection, and cancer, with potential applications in biomarker development and therapeutic intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.